{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:39:23Z","timestamp":1783010363849,"version":"3.54.6"},"reference-count":275,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL171220"],"award-info":[{"award-number":["R01HL171220"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL171220"],"award-info":[{"award-number":["R01HL171220"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.phrs.2025.107659","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:16:21Z","timestamp":1739924181000},"page":"107659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases"],"prefix":"10.1016","volume":"213","author":[{"given":"Boyu","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargis","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nnano.2008.114","article-title":"Seven challenges for nanomedicine","volume":"3","author":"Sanhai","year":"2008","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/17460441.2017.1290077","article-title":"Future strategies for the discovery of therapeutic aptamers","volume":"12","author":"Yoon","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib4","first-page":"27","article-title":"RNA aptamers and their therapeutic and diagnostic applications","volume":"4","author":"Germer","year":"2013","journal-title":"Int. J. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib6","first-page":"774","article-title":"FDA approves second RNA aptamer","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10440","key":"10.1016\/j.phrs.2025.107659_bib7","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet (Lond., Engl. )"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/eurheartj\/ehu178","article-title":"Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study","volume":"36","author":"M\u00f6ckel","year":"2015","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.phrs.2025.107659_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1164\/rccm.201604-0690SO","article-title":"Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care","volume":"194","author":"Roversi","year":"2016","journal-title":"Am. J. Respir. Crit. care Med."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11095-019-2721-5","article-title":"Pharmacokinetic\/pharmacodynamics modeling of drug-loaded PLGA nanoparticles targeting heterogeneously vascularized tumor tissue","volume":"36","author":"Miller","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107659_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2025.107659_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115302","article-title":"Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics","volume":"208","author":"Gil-Cabrerizo","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6287","key":"10.1016\/j.phrs.2025.107659_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"issue":"4968","key":"10.1016\/j.phrs.2025.107659_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Sci. (N. Y., N. Y. )"},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102142","article-title":"Recent advances in SELEX technology and aptamer applications in biomedicine","volume":"18","author":"Zhuo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.107659_bib16","doi-asserted-by":"crossref","first-page":"12301","DOI":"10.1021\/acsnano.9b06522","article-title":"Aptamers as modular components of therapeutic nucleic acid nanotechnology","volume":"13","author":"Panigaj","year":"2019","journal-title":"ACS nano"},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib17","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.bbagen.2018.07.029","article-title":"Recent developments in cell-SELEX technology for aptamer selection","volume":"1862","author":"Kaur","year":"2018","journal-title":"Biochim. Et. Biophys. Acta Gen. Subj."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2025.107659_bib18","article-title":"Recent progress of SELEX methods for screening nucleic acid aptamers","volume":"266","author":"Zhu","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.phrs.2025.107659_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108461","article-title":"Design and application of microfluidics in aptamer SELEX and Aptasensors","volume":"77","author":"Zhang","year":"2024","journal-title":"Biotechnol. Adv."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050941","article-title":"Recent advances in aptamer discovery and applications","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges, nature reviews","volume":"16","author":"Zhou","year":"2017","journal-title":"Drug Discov."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s12276-022-00760-w","article-title":"An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration","volume":"54","author":"Yunn","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib23","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.ymthe.2021.06.010","article-title":"Aptamers: cutting edge of cancer therapies","volume":"29","author":"Shigdar","year":"2021","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.phrs.2025.107659_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fgene.2012.00234","article-title":"Current progress of RNA aptamer-based therapeutics","volume":"3","author":"Zhou","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.phrs.2025.107659_bib25","article-title":"Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-\u03b2-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma","volume":"174","author":"Hao","year":"2024","journal-title":"Biomed. Pharmacother. =Biomedecine Pharmacother."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib26","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1021\/acsnano.5b02471","article-title":"Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing rna nanotechnology","volume":"9","author":"Shu","year":"2015","journal-title":"ACS nano"},{"key":"10.1016\/j.phrs.2025.107659_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.addr.2021.04.011","article-title":"Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects","volume":"173","author":"Johnson","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib28","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/acs.biomac.2c00169","article-title":"Fluorescence-shadowing nanoparticle clusters for real-time monitoring of tumor progression","volume":"23","author":"Pham-Nguyen","year":"2022","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/acsnano.6b05737","article-title":"Advancement of the emerging field of RNA nanotechnology","volume":"11","author":"Jasinski","year":"2017","journal-title":"ACS nano"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1261\/rna.037002.112","article-title":"Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs","volume":"19","author":"Shu","year":"2013","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nnano.2011.105","article-title":"Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics","volume":"6","author":"Shu","year":"2011","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.nantod.2012.06.010","article-title":"Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers","volume":"7","author":"Haque","year":"2012","journal-title":"Nano Today"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib34","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/acsnano.5b01552","article-title":"Spatiotemporal targeting of a dual-ligand nanoparticle to cancer metastasis","volume":"9","author":"Doolittle","year":"2015","journal-title":"ACS nano"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/nn506963h","article-title":"Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers","volume":"9","author":"He","year":"2015","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/nn800669n","article-title":"Shedding light on tumors using nanoparticles","volume":"2","author":"Rao","year":"2008","journal-title":"ACS nano"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib37","doi-asserted-by":"crossref","first-page":"12814","DOI":"10.1021\/acsnano.8b07954","article-title":"Modular nanoparticulate prodrug design enables efficient treatment of solid tumors using bioorthogonal activation","volume":"12","author":"Miller","year":"2018","journal-title":"ACS nano"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-020-14780-5","article-title":"Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.phrs.2025.107659_bib39","article-title":"RNA nanotechnology to solubilize hydrophobic antitumor drug for targeted delivery","volume":"6","author":"Piao","year":"2019","journal-title":"Adv. Sci. (Weinh., Baden. -Wurtt., Ger. )"},{"issue":"5454","key":"10.1016\/j.phrs.2025.107659_bib40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1126\/science.287.5454.820","article-title":"Adaptive recognition by nucleic acid aptamers","volume":"287","author":"Hermann","year":"2000","journal-title":"Sci. (N. Y., N. Y. )"},{"issue":"16","key":"10.1016\/j.phrs.2025.107659_bib41","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1073\/pnas.1017999108","article-title":"Self-assembling RNA square","volume":"108","author":"Dibrov","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41467-019-08521-6","article-title":"Versatile kit of robust nanoshapes self-assembling from RNA and DNA modules","volume":"10","author":"Monferrer","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nmat3253","article-title":"Self-assembled RNA interference microsponges for efficient siRNA delivery","volume":"11","author":"Lee","year":"2012","journal-title":"Nat. Mater."},{"key":"10.1016\/j.phrs.2025.107659_bib44","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1038\/ncomms5367","article-title":"Self-assembly of free-standing RNA membranes","volume":"5","author":"Han","year":"2014","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/nar\/29.2.455","article-title":"TectoRNA: modular assembly units for the construction of RNA nano-objects","volume":"29","author":"Jaeger","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10.1016\/j.phrs.2025.107659_bib46","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1021\/acs.chemrev.1c00009","article-title":"Thermostability, tunability, and tenacity of RNA as rubbery anionic polymeric materials in nanotechnology and nanomedicine-specific cancer targeting with undetectable toxicity","volume":"121","author":"Binzel","year":"2021","journal-title":"Chem. Rev."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nnano.2010.231","article-title":"The emerging field of RNA nanotechnology","volume":"5","author":"Guo","year":"2010","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib48","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/nl0494497","article-title":"Bottom-up assembly of RNA arrays and superstructures as potential parts in nanotechnology","volume":"4","author":"Shu","year":"2004","journal-title":"Nano Lett."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib49","first-page":"820","article-title":"Computational design strategies for RNA nanostructures","volume":"26","author":"Shapiro","year":"2009","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.phrs.2025.107659_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/rnan-2013-0001","article-title":"Engineered RNA nanodesigns for applications in RNA nanotechnology","volume":"1","author":"Afonin","year":"2013","journal-title":"DNA RNA Nanotechnol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib51","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1021\/acsnano.7b08777","article-title":"Rationally designed polycationic carriers for potent polymeric siRNA-mediated gene silencing","volume":"12","author":"Wu","year":"2018","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib52","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/mt.2016.85","article-title":"Specific delivery of MiRNA for high efficient inhibition of prostate cancer by RNA nanotechnology","volume":"24","author":"Binzel","year":"2016","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib53","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1021\/nn502160s","article-title":"Physicochemically tunable polyfunctionalized RNA square architecture with fluorogenic and ribozymatic properties","volume":"8","author":"Jasinski","year":"2014","journal-title":"ACS nano"},{"key":"10.1016\/j.phrs.2025.107659_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/15476286.2021.1915620","article-title":"RNA nanotechnology to build a dodecahedral genome of single-stranded RNA virus","author":"Li","year":"2021","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41565-017-0012-z","article-title":"Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression","volume":"13","author":"Pi","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.nano.2015.11.008","article-title":"Controllable self-assembly of RNA dendrimers","volume":"12","author":"Sharma","year":"2016","journal-title":"Nanomedicine"},{"issue":"45","key":"10.1016\/j.phrs.2025.107659_bib57","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1002\/adma.201603180","article-title":"Fabrication of RNA 3D nanoprisms for loading and protection of small RNAS and model drugs","volume":"28","author":"Khisamutdinov","year":"2016","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12274-018-2174-x","article-title":"Photo-controlled release of paclitaxel and model drugs from RNA pyramids","volume":"12","author":"Xu","year":"2019","journal-title":"Nano Res"},{"key":"10.1016\/j.phrs.2025.107659_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2018.02.014","article-title":"RNA-based micelles: a novel platform for paclitaxel loading and delivery","volume":"276","author":"Shu","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.phrs.2025.107659_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101085","article-title":"Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-gamma-linolenic acid for colon cancer suppression","volume":"21","author":"Xu","year":"2019","journal-title":"Redox Biol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nnano.2010.160","article-title":"In vitro assembly of cubic RNA-based scaffolds designed in silico","volume":"5","author":"Afonin","year":"2010","journal-title":"Nat. Nanotechnol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib62","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/nprot.2011.418","article-title":"Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine","volume":"6","author":"Afonin","year":"2011","journal-title":"Nat. Protoc."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib63","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1021\/nl502385k","article-title":"Multifunctional RNA nanoparticles","volume":"14","author":"Afonin","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.phrs.2025.107659_bib64","first-page":"153","article-title":"RNA aptamers: a review of recent trends and applications","volume":"131","author":"Kang","year":"2013","journal-title":"Adv. Biochem Eng. Biotechnol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.coph.2010.07.002","article-title":"Therapeutic applications of ribozymes and riboswitches","volume":"10","author":"Mulhbacher","year":"2010","journal-title":"Curr. Opin. Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib66","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/anie.201508978","article-title":"A Multi-RNAi microsponge platform for simultaneous controlled delivery of multiple small interfering RNAs","volume":"55","author":"Roh","year":"2016","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/wrna.1111","article-title":"Current advances in Phi29 pRNA biology and its application in drug delivery","volume":"3","author":"Ye","year":"2012","journal-title":"Wiley Inter. Rev. RNA"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nnano.2011.191","article-title":"Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population","volume":"7","author":"Kim","year":"2011","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nnano.2008.30","article-title":"Nanoparticle-mediated cellular response is size-dependent","volume":"3","author":"Jiang","year":"2008","journal-title":"Nat. Nanotechnol."},{"issue":"13","key":"10.1016\/j.phrs.2025.107659_bib70","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","article-title":"Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles","volume":"31","author":"He","year":"2010","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib71","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1021\/nl072471q","article-title":"Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles","volume":"7","author":"Giljohann","year":"2007","journal-title":"Nano Lett."},{"key":"10.1016\/j.phrs.2025.107659_bib72","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","author":"Frohlich","year":"2012","journal-title":"Int. J. Nanomed. 7"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nnano.2011.58","article-title":"The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles","volume":"6","author":"Cho","year":"2011","journal-title":"Nat. Nanotechnol."},{"issue":"14","key":"10.1016\/j.phrs.2025.107659_bib74","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib75","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nnano.2013.181","article-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology","volume":"8","author":"Tenzer","year":"2013","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/17435390.2012.655342","article-title":"Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses","volume":"7","author":"Deng","year":"2013","journal-title":"Nanotoxicology"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nnano.2016.269","article-title":"Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo","volume":"12","author":"Chen","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib79","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acscombsci.6b00073","article-title":"Cellular delivery of RNA nanoparticles","volume":"18","author":"Parlea","year":"2016","journal-title":"ACS Comb. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib80","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bpj.2017.02.022","article-title":"Understanding the relative flexibility of RNA and DNA duplexes: stretching and twist-stretch coupling","volume":"112","author":"Bao","year":"2017","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsb.2016.06.022","article-title":"Probing the mechanical properties, conformational changes, and interactions of nucleic acids with magnetic tweezers","volume":"197","author":"Kriegel","year":"2017","journal-title":"J. Struct. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003756","article-title":"Blind predictions of DNA and RNA tweezers experiments with force and torque","volume":"10","author":"Chou","year":"2014","journal-title":"PLoS Comput. Biol."},{"issue":"43","key":"10.1016\/j.phrs.2025.107659_bib83","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1407197111","article-title":"Double-stranded RNA under force and torque: similarities to and striking differences from double-stranded DNA","volume":"111","author":"Lipfert","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib84","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1021\/acsnano.0c04863","article-title":"RNA Nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity","volume":"14","author":"Ghimire","year":"2020","journal-title":"ACS nano"},{"key":"10.1016\/j.phrs.2025.107659_bib85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2020.12.007","article-title":"Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance","volume":"330","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2025.107659_bib86","article-title":"Non-Small-cell lung cancer regression by siRNA delivered through exosomes that display EGFR RNA aptamer","author":"Li","year":"2021","journal-title":"Nucleic Acid. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib87","article-title":"Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation","volume":"12","author":"Guo","year":"2020","journal-title":"Wiley Inter. Rev. Nanomed. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib88","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ymthe.2019.04.018","article-title":"Delivery of Anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD133","volume":"27","author":"Yin","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib89","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on siRNA-based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"32","key":"10.1016\/j.phrs.2025.107659_bib90","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1073\/pnas.0703778104","article-title":"Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes","volume":"104","author":"Rozema","year":"2007","journal-title":"P Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde.11.155","article-title":"Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects","volume":"3","author":"Seth","year":"2012","journal-title":"Ther. Deliv."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib92","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/mt.2011.35","article-title":"Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery","volume":"19","author":"Abdelmawla","year":"2011","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/nn1024658","article-title":"Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging","volume":"5","author":"Liu","year":"2011","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib94","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1261\/rna.037077.112","article-title":"Crystal structure of 3WJ Core revealing divalent ion-promoted thermostability and assembly of the Phi29 Hexameric Motor pRNA","volume":"19","author":"Zhang","year":"2013","journal-title":"RNA"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib95","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/nprot.2013.097","article-title":"Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells","volume":"8","author":"Shu","year":"2013","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib96","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt885","article-title":"Programmable folding of fusion RNA in vivo and in vitro driven by pRNA 3WJ motif of phi29 DNA packaging motor","volume":"42","author":"Shu","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib97","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/nat.2012.0380","article-title":"Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells","volume":"22","author":"Reif","year":"2012","journal-title":"Nucleic Acid. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib98","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s11095-013-1226-x","article-title":"Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection","volume":"31","author":"Feng","year":"2014","journal-title":"Pharm. Res"},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib99","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/mt.2011.23","article-title":"Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach","volume":"19","author":"Shu","year":"2011","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1089\/hum.2005.16.1097","article-title":"Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA","volume":"16","author":"Guo","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib101","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/nl051264s","article-title":"Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology","volume":"5","author":"Khaled","year":"2005","journal-title":"Nano Lett."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib102","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.gt.3302716","article-title":"Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells","volume":"13","author":"Guo","year":"2006","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"E.L.A","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib104","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib105","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib106","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncb1725","article-title":"Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells","volume":"10","author":"Al-Nedawi","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib107","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2012.08.008","article-title":"Exosomes for targeted siRNA delivery across biological barriers","volume":"65","author":"El Andaloussi","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2025.107659_bib108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Rufino-Ramos","year":"2017","journal-title":"J. Control Release"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib109","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1021\/acsnano.9b04397","article-title":"Tumor-Derived extracellular vesicles breach the intact blood-brain barrier via transcytosis","volume":"13","author":"Morad","year":"2019","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040851","article-title":"Targeting and crossing the blood-brain barrier with extracellular vesicles","volume":"9","author":"Saint-Pol","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib111","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jconrel.2011.11.021","article-title":"Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery","volume":"161","author":"van Dommelen","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.phrs.2025.107659_bib113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2019.08.021","article-title":"Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping","volume":"311-312","author":"Zheng","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1097-2765(00)80124-0","article-title":"Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation","volume":"2","author":"Guo","year":"1998","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.phrs.2025.107659_bib115","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1261\/rna.057646.116","article-title":"Mechanism of three-component collision to produce ultrastable pRNA three-way Junction of Phi29 DNA-packaging motor by kinetic assessment","volume":"22","author":"Binzel","year":"2016","journal-title":"RNA"},{"issue":"14","key":"10.1016\/j.phrs.2025.107659_bib116","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1021\/bi4017022","article-title":"Entropy-driven One-step Formation of Phi29 pRNA 3WJ from Three RNA Fragments","volume":"53","author":"Binzel","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib117","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1261\/rna.063057.117","article-title":"Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2\u2032-F RNA, and LNA in the context of Phi29 pRNA 3WJ","volume":"24","author":"Piao","year":"2018","journal-title":"RNA"},{"key":"10.1016\/j.phrs.2025.107659_bib118","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtn.2017.10.010","article-title":"Size, Shape, and Sequence-Dependent Immunogenicity of RNA Nanoparticles","volume":"9","author":"Guo","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib119","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005543","article-title":"Coronary atherosclerotic vulnerable plaque: current perspectives","volume":"6","author":"Stefanadis","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib121","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin Toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib122","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force","volume":"328","author":"Chou","year":"2022","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib123","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects","volume":"78","author":"Mo\u00dfhammer","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib124","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ymthe.2019.03.016","article-title":"Preclinical development of a vWF aptamer to limit thrombosis and engender arterial recanalization of occluded vessels","volume":"27","author":"Nimjee","year":"2019","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib125","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000830","article-title":"Aptamers targeting von willebrand factor: what and why?","volume":"7","author":"Schutgens","year":"2023","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib126","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib127","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","article-title":"The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial","volume":"107","author":"Kovacevic","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib128","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.14755","article-title":"The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer","volume":"18","author":"Zhu","year":"2020","journal-title":"J. Thromb. Haemost.: JTH"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib129","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/s41598-021-82747-7","article-title":"The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients","volume":"11","author":"Kovacevic","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jbiosc.2020.10.009","article-title":"In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake","volume":"131","author":"Ando","year":"2021","journal-title":"J. Biosci. Bioeng."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/nat.2010.0270","article-title":"RNA aptamer therapy for vaso-occlusion in sickle cell disease","volume":"21","author":"Burnette","year":"2011","journal-title":"Nucleic Acid. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib132","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1432-1327.1998.2520553.x","article-title":"Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function","volume":"252","author":"Gal","year":"1998","journal-title":"Eur. J. Biochem."},{"issue":"33","key":"10.1016\/j.phrs.2025.107659_bib133","doi-asserted-by":"crossref","first-page":"28858","DOI":"10.1074\/jbc.M111.273292","article-title":"Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis","volume":"286","author":"Mahmood","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.phrs.2025.107659_bib134","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2007.02.059","article-title":"Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior","volume":"49","author":"Chatzizisis","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043836","article-title":"Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection","volume":"7","author":"Thiel","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2025.107659_bib136","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.omtn.2019.03.005","article-title":"Delivery of cell-specific aptamers to the arterial wall with an occlusion perfusion catheter","volume":"16","author":"Udofot","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib137","article-title":"Smooth muscle cell-targeted RNA ligand promotes accelerated reendothelialization in a swine peripheral injury model, Molecular therapy","volume":"34","author":"Lei","year":"2023","journal-title":"Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib138","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.omtn.2022.08.007","article-title":"Local intraluminal delivery of a smooth muscle-targeted RNA ligand inhibits neointima growth in a porcine model of peripheral vascular disease","volume":"29","author":"Yazdani","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib139","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/nat.2017.0711","article-title":"Cell-SELEX-Based Identification of a human and mouse cross-reactive endothelial cell-internalizing aptamer","volume":"28","author":"Dua","year":"2018","journal-title":"Nucleic Acid. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib140","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib141","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: a neglected therapeutic target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"15","key":"10.1016\/j.phrs.2025.107659_bib142","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib143","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib144","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13339","article-title":"Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B","volume":"104","author":"Marlar","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"19","key":"10.1016\/j.phrs.2025.107659_bib145","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1093\/eurheartj\/ehr179","article-title":"Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy","volume":"32","author":"Povsic","year":"2011","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib146","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/2048872617703065","article-title":"Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes","volume":"8","author":"Staudacher","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc. care"},{"issue":"23","key":"10.1016\/j.phrs.2025.107659_bib147","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"issue":"31","key":"10.1016\/j.phrs.2025.107659_bib148","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib149","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fca.12.5","article-title":"The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome","volume":"8","author":"Vavalle","year":"2012","journal-title":"Future Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib150","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10016","key":"10.1016\/j.phrs.2025.107659_bib151","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107659_bib152","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtn.2021.12.011","article-title":"Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO","volume":"27","author":"Reed","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib153","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biochi.2016.09.018","article-title":"The efficient cell-SELEX strategy, Icell-SELEX, using isogenic cell lines for selection and counter-selection to generate RNA aptamers to cell surface proteins","volume":"131","author":"Takahashi","year":"2016","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib154","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41467-017-01097-z","article-title":"\u03b1v integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis","volume":"8","author":"Murray","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib155","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jth.13760","article-title":"A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release","volume":"15","author":"Steen Burrell","year":"2017","journal-title":"J. Thromb. Haemost.: JTH"},{"issue":"9970","key":"10.1016\/j.phrs.2025.107659_bib156","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure: the Lancet lecture","volume":"385","author":"Braunwald","year":"2015","journal-title":"Lancet (Lond., Engl. )"},{"issue":"18","key":"10.1016\/j.phrs.2025.107659_bib157","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib158","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.123.067373","article-title":"RNA Therapeutics for the Cardiovascular System","volume":"149","author":"Dzau","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107659_bib159","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omtn.2018.11.001","article-title":"A chymase inhibitory RNA aptamer improves cardiac function and survival after myocardial infarction","volume":"14","author":"Jin","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cvr\/cvx016","article-title":"Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure","volume":"113","author":"Li","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib161","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193392","article-title":"An anti-PDGFR\u03b2 aptamer for selective delivery of small therapeutic peptide to cardiac cells","volume":"13","author":"Romanelli","year":"2018","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib162","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.str.2012.05.002","article-title":"Molecular mechanism for inhibition of g protein-coupled receptor kinase 2 by a selective RNA aptamer","volume":"20","author":"Tesmer","year":"2012","journal-title":"Struct. (Lond., Engl.: 1993)"},{"issue":"20","key":"10.1016\/j.phrs.2025.107659_bib163","doi-asserted-by":"crossref","first-page":"8763","DOI":"10.1021\/ac3020643","article-title":"An RNA aptamer-based microcantilever sensor to detect the inflammatory marker, mouse lipocalin-2","volume":"84","author":"Zhai","year":"2012","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib164","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00216-011-5174-1","article-title":"C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP","volume":"401","author":"Wang","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib165","article-title":"High-affinity RNA aptamers to C-reactive protein (CRP): newly developed pre-elution methods for aptamer selection","volume":"352","author":"Orito","year":"2012","journal-title":"J. Phys.: Conf. Ser."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib166","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: a Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib167","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib168","first-page":"3750","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer, clinical cancer research: an official journal of the","volume":"11","author":"Chou","year":"2005","journal-title":"Am. Assoc. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107659_bib169","article-title":"Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer, molecular therapy","volume":"34","author":"Thomas","year":"2023","journal-title":"Nucleic Acids"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024071","article-title":"A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death","volume":"6","author":"Esposito","year":"2011","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.phrs.2025.107659_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194700","article-title":"Efficient Epidermal growth factor receptor targeting oligonucleotide as a potential molecule for targeted cancer therapy","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib172","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.mt.6300320","article-title":"RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin","volume":"16","author":"Mi","year":"2008","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib173","article-title":"Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL","volume":"5","author":"Iaboni","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib174","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.omtn.2017.12.003","article-title":"In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library","volume":"10","author":"Wang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib175","article-title":"Characterization of a bifunctional synthetic rna aptamer and a truncated form for ability to inhibit growth of non-small cell lung Cancer","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib176","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2012.11.032","article-title":"RNA aptamers targeting cancer stem cell marker CD133","volume":"330","author":"Shigdar","year":"2013","journal-title":"Cancer Lett."},{"issue":"15","key":"10.1016\/j.phrs.2025.107659_bib177","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1073\/pnas.1913242117","article-title":"In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers","volume":"117","author":"Bell","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib178","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/nar\/gkn967","article-title":"Phototoxic aptamers selectively enter and kill epithelial cancer cells","volume":"37","author":"Ferreira","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.phrs.2025.107659_bib179","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1074-5521(00)00032-6","article-title":"RNA aptamers as pathway-specific MAP kinase inhibitors","volume":"7","author":"Seiwert","year":"2000","journal-title":"Chem. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib180","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.5012\/bkcs.2009.30.8.1827","article-title":"Isolation of RNA Aptamers Targeting HER-2-overexpressing Breast Cancer Cells Using Cell-SELEX","volume":"30","author":"Kang","year":"2009","journal-title":"Bull. Korean Chem. Soc."},{"issue":"23","key":"10.1016\/j.phrs.2025.107659_bib181","doi-asserted-by":"crossref","first-page":"14309","DOI":"10.1074\/jbc.273.23.14309","article-title":"RNA molecules that bind to and inhibit the active site of a tyrosine phosphatase","volume":"273","author":"Bell","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.phrs.2025.107659_bib182","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1158\/0008-5472.CAN-06-2526","article-title":"Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells","volume":"66","author":"Lee","year":"2006","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.phrs.2025.107659_bib183","doi-asserted-by":"crossref","first-page":"9226","DOI":"10.1073\/pnas.1332660100","article-title":"Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3","volume":"100","author":"Chen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib184","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.277","article-title":"In vivo selection of tumor-targeting RNA motifs","volume":"6","author":"Mi","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"23","key":"10.1016\/j.phrs.2025.107659_bib185","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1073\/pnas.90.23.11227","article-title":"High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding","volume":"90","author":"Jellinek","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"30","key":"10.1016\/j.phrs.2025.107659_bib186","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1021\/bi000149n","article-title":"Molecular recognition of cAMP by an RNA aptamer","volume":"39","author":"Koizumi","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2025.107659_bib187","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymeth.2018.02.025","article-title":"Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor","volume":"143","author":"Guo","year":"2018","journal-title":"Methods (San. Diego, Calif. )"},{"key":"10.1016\/j.phrs.2025.107659_bib188","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtn.2023.07.027","article-title":"Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles","volume":"33","author":"Yang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122432","article-title":"RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity","volume":"305","author":"Li","year":"2024","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib190","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/acs.molpharmaceut.3c00845","article-title":"In Vitro and In Vivo Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles","volume":"21","author":"Jin","year":"2024","journal-title":"Mol. Pharm."},{"issue":"14","key":"10.1016\/j.phrs.2025.107659_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25143138","article-title":"Aptamers in Non-Small Cell Lung Cancer Treatment","volume":"25","author":"Wieleba","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib192","first-page":"73","article-title":"Pulmonary hypertension","volume":"114","author":"Hoeper","year":"2017","journal-title":"Dtsch. Arzteblatt Int."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib193","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41420-023-01535-6","article-title":"Molecular regulation and therapeutic implications of cell death in pulmonary hypertension","volume":"9","author":"Wang","year":"2023","journal-title":"Cell death Discov."},{"issue":"23","key":"10.1016\/j.phrs.2025.107659_bib194","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1161\/CIRCULATIONAHA.111.034512","article-title":"A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension","volume":"124","author":"Zaiman","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib195","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/rr44","article-title":"Role of endothelin-1 in lung disease","volume":"2","author":"Fagan","year":"2001","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib196","first-page":"62","article-title":"The role of endothelin-1 in pulmonary arterial hypertension","volume":"2014","author":"Chester","year":"2014","journal-title":"Glob. Cardiol. Sci. Pract."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib197","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.atherosclerosissup.2012.10.029","article-title":"Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension","volume":"14","author":"Dandel","year":"2013","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.phrs.2025.107659_bib198","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2015.11.001","article-title":"Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: a vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies","volume":"244","author":"Wallukat","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2025.107659_bib199","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2016.06.061","article-title":"Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors","volume":"789","author":"Haberland","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib200","doi-asserted-by":"crossref","first-page":"L826","DOI":"10.1152\/ajplung.00199.2002","article-title":"Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus","volume":"284","author":"Balasubramaniam","year":"2003","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib201","doi-asserted-by":"crossref","DOI":"10.3390\/life12050658","article-title":"The Platelet-Derived Growth Factor Pathway in Pulmonary Arterial Hypertension: Still an Interesting Target?","volume":"12","author":"Solinc","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.phrs.2025.107659_bib202","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/01.fjc.0000166216.27544.22","article-title":"Transforming growth factor-beta induces endothelin-1 expression through activation of the Smad signaling pathway","volume":"44 1","author":"Rodr\u00edguez-Pascual","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib203","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib204","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.21037\/jtd-23-1781","article-title":"A narrative review of theophylline: is there still a place for an old friend?","volume":"16","author":"Scurek","year":"2024","journal-title":"J. Thorac. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib205","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: Targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin. Exp. Allergy: J. Br. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2025.107659_bib206","series-title":"Treasure Island (FL) ineligible companies. Disclosure: Mary Cataletto declares no relevant financial relationships with ineligible companies","article-title":"Asthma, StatPearls, StatPearls Publishing Copyright \u00a9 2024","author":"Hashmi","year":"2024"},{"key":"10.1016\/j.phrs.2025.107659_bib207","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbrc.2022.04.043","article-title":"Discovery of IL-5-binding unnatural cyclic peptides from multiple libraries by directed evolution","volume":"610","author":"Fuji","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107659_bib208","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtn.2018.05.023","article-title":"A Synthetic Cross-species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo","volume":"12","author":"Prodeus","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib209","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1016\/S2214-109X(23)00217-6","article-title":"The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study","volume":"11","author":"Chen","year":"2023","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/resp.12882","article-title":"Transforming growth factor (TGF) \u03b2(1) and Smad signalling pathways: a likely key to EMT-associated COPD pathogenesis","volume":"22","author":"Mahmood","year":"2017","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib211","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2018.11.017","article-title":"A neutralizing aptamer to TGFBR2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-\u03b2-Mediated CFTR expression","volume":"27","author":"Dutta","year":"2019","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib212","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5858\/arpa.2015-0519-RA","article-title":"Acute lung injury: a clinical and molecular review","volume":"140","author":"Butt","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib213","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pccm.2024.04.002","article-title":"Mechanisms of pulmonary endothelial barrier dysfunction in acute lung injury and acute respiratory distress syndrome","volume":"2","author":"Su","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. care Med."},{"key":"10.1016\/j.phrs.2025.107659_bib214","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2019.06.011","article-title":"The deubiquitinase USP13 stabilizes the anti-inflammatory receptor IL-1R8\/Sigirr to suppress lung inflammation","volume":"45","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib215","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/CCM.0b013e3182451c87","article-title":"Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance","volume":"40","author":"Calfee","year":"2012","journal-title":"Crit. care Med."},{"key":"10.1016\/j.phrs.2025.107659_bib216","unstructured":"K. Schlosser, S.H. Mei, Y. Deng, D.J. Stewart, Abstract 14803: Treatment of Endotoxin-Induced Acute Lung Injury in Mice by Aptamer-Mediated Inhibition of Angiopoietin-2, 122(suppl_21) (2010) A14803-A14803."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib217","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/thoraxjnl-2017-210413","article-title":"High circulating angiopoietin-2 levels exacerbate pulmonary inflammation but not vascular leak or mortality in endotoxin-induced lung injury in mice","volume":"73","author":"Schlosser","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2025.107659_bib218","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.omtn.2023.02.021","article-title":"Jr., Inhalation of an RNA aptamer that selectively binds extracellular histones protects from acute lung injury","volume":"31","author":"Lei","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.phrs.2025.107659_bib219","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.omtn.2023.05.009","article-title":"Inhaled aptamer therapy: a hopeful therapy for lung disease","volume":"32","author":"Martin","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib220","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.52","article-title":"The role of extracellular histone in organ injury","volume":"8","author":"Silk","year":"2017","journal-title":"Cell death Dis."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib221","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1261\/rna.878908","article-title":"3rd, Selection and characterization of anti-NF-kappaB p65 RNA aptamers","volume":"14","author":"Wurster","year":"2008","journal-title":"RNA"},{"issue":"10","key":"10.1016\/j.phrs.2025.107659_bib222","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1021\/bi982515x","article-title":"3rd, Selection and characterization of an RNA decoy for transcription factor NF-kappa B","volume":"38","author":"Lebruska","year":"1999","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib223","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.5012\/bkcs.2010.31.12.3561","article-title":"Generation of Antagonistic RNA aptamers specific to proinflammatory cytokine interleukin-32","volume":"31","author":"Kim","year":"2010","journal-title":"Bull. Korean Chem. Soc."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib224","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/mt.2012.18","article-title":"Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing","volume":"20","author":"Berezhnoy","year":"2012","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s13213-013-0720-z","article-title":"In vitro selection of RNA aptamer specific to Staphylococcus aureus","volume":"64","author":"Han","year":"2014","journal-title":"Ann. Microbiol."},{"issue":"166","key":"10.1016\/j.phrs.2025.107659_bib226","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0051-2022","article-title":"Respiratory viruses: their importance and lessons learned from COVID-19","volume":"31","author":"Cilloniz","year":"2022","journal-title":"Eur. Respir. Rev.: Off. J. Eur. Respir. Soc."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib227","article-title":"Single cell analysis of lung lymphatic endothelial cells and lymphatic responses during influenza infection","volume":"1","author":"Ge","year":"2024","journal-title":"J. Respir. Biol. Transl. Med."},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib228","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbrc.2007.12.020","article-title":"Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase\/Helicase","volume":"366","author":"Jang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.phrs.2025.107659_bib229","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.1021\/acs.analchem.0c01394","article-title":"Discovery of aptamers targeting the receptor-binding domain of the SARS-CoV-2 spike glycoprotein","volume":"92","author":"Song","year":"2020","journal-title":"Anal. Chem."},{"issue":"50","key":"10.1016\/j.phrs.2025.107659_bib230","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112942118","article-title":"A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry","volume":"118","author":"Valero","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/cells13050422","article-title":"Therapeutic Effects of a novel aptamer on coronaviral infection-induced lung injury and systemic inflammatory responses","volume":"13","author":"Wang","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib232","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1785","article-title":"Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era","volume":"14","author":"Dzuvor","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib233","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084168","article-title":"Aptamers for anti-viral therapeutics and diagnostics","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 3","key":"10.1016\/j.phrs.2025.107659_bib234","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1099\/vir.0.81508-0","article-title":"An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion","volume":"87","author":"Gopinath","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/j.phrs.2025.107659_bib235","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1016\/j.actbio.2013.06.016","article-title":"Aptamers that bind to the hemagglutinin of the recent pandemic influenza virus H1N1 and efficiently inhibit agglutination","volume":"9","author":"Gopinath","year":"2013","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib236","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/nat.2011.0321","article-title":"Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus","volume":"21","author":"Park","year":"2011","journal-title":"Nucleic Acid. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib237","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097574","article-title":"An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells","volume":"9","author":"Kwon","year":"2014","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib238","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.actbio.2013.12.034","article-title":"An aptamer that binds efficiently to the hemagglutinins of highly pathogenic avian influenza viruses (H5N1 and H7N7) and inhibits hemagglutinin-glycan interactions","volume":"10","author":"Suenaga","year":"2014","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.phrs.2025.107659_bib239","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/rna.9.1.18062","article-title":"Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells","volume":"9","author":"Meyer","year":"2012","journal-title":"RNA Biol."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib240","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/bbb\/zbaa124","article-title":"In vitro selection of an RNA aptamer yields an interleukin-6\/interleukin-6 receptor interaction inhibitor","volume":"85","author":"Ando","year":"2021","journal-title":"Biosci., Biotechnol., Biochem."},{"issue":"2006","key":"10.1016\/j.phrs.2025.107659_bib241","first-page":"251","article-title":"Isolation of RNA aptamers against human Toll-like receptor 3 ectodomain","volume":"50","author":"Watanabe","year":"2004","journal-title":"Nucleic Acids Symp. . Ser."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib242","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1165\/rcmb.2017-0402ED","article-title":"Fibroblast-matrix cross-talk in idiopathic pulmonary fibrosis: cross-links at the crossroads","volume":"58","author":"Bitterman","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib243","article-title":"Arrestin beta 1 regulates alveolar progenitor renewal and lung fibrosis","volume":"1","author":"Huang","year":"2024","journal-title":"J. Respir. Biol. Transl. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib244","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pccm.2024.04.003","article-title":"Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction","volume":"2","author":"Zheng","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. care Med."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib245","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib246","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2025.107659_bib247","first-page":"1010","article-title":"Pirfenidone inhibits transforming growth factor-\u03b21-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19","volume":"18","author":"Choi","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.phrs.2025.107659_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104321","article-title":"Discovery of cell-internalizing artificial nucleic acid aptamers for lung fibroblasts and targeted drug delivery","volume":"105","author":"Uemachi","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib249","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.biopha.2010.01.006","article-title":"Inhibition of type III TGF-\u03b2 receptor aggravates lung fibrotic process","volume":"64","author":"Ahn","year":"2010","journal-title":"Biomed. Pharmacother. =\u2009Biomedecine Pharmacother."},{"issue":"7","key":"10.1016\/j.phrs.2025.107659_bib250","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.biochi.2006.02.004","article-title":"Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface","volume":"88","author":"Ohuchi","year":"2006","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2025.107659_bib251","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.redox.2015.11.006","article-title":"Role of redoximiRs in fibrogenesis","volume":"7","author":"Fierro-Fern\u00e1ndez","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2025.107659_bib252","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.628991","article-title":"From Flies to Men: ROS and the NADPH Oxidase in Phagocytes","volume":"9","author":"Moghadam","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2025.107659_bib253","unstructured":"Development of RNA aptamers targeting the NADPH oxidase DUOX1 as a therapeutic approach to treat lung fibrosis \u2013 APFIBROX. \u3008https:\/\/anr.fr\/en\/funded-projects-and-impact\/funded-projects\/project\/funded\/project\/b2d9d3668f92a3b9fbbf7866072501ef-18eb0a94dc\/?tx_anrprojects_funded%5Bcontroller%5D=Funded&cHash=e283cc0629ef3553787b96792c02c110\u3009. (Accessed June 28 2024)."},{"issue":"6","key":"10.1016\/j.phrs.2025.107659_bib254","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2017.0680","article-title":"Effect of chemical modifications on aptamer stability in serum","volume":"27","author":"Kratschmer","year":"2017","journal-title":"Nucleic Acid. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1261\/rna.079503.122","article-title":"Applications and future of aptamers that achieve rapid-onset anticoagulation","volume":"29","author":"Yu","year":"2023","journal-title":"RNA"},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib256","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib257","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2025.107659_bib258","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.omtn.2022.07.012","article-title":"Minding the gap: Unlockingthe therapeutic potentialof aptamers and making up for lost time, Molecular therapy","volume":"29","author":"Di Ruscio","year":"2022","journal-title":"Nucleic Acids"},{"issue":"3","key":"10.1016\/j.phrs.2025.107659_bib259","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.phrs.2025.107659_bib260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as Therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"27","key":"10.1016\/j.phrs.2025.107659_bib261","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.2174\/092986711797189600","article-title":"Nucleic acid aptamers: clinical applications and promising new horizons","volume":"18","author":"Ni","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib262","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020356","article-title":"Design and prediction of aptamers assisted by in silico methods","volume":"11","author":"Lee","year":"2023","journal-title":"Biomedicines"},{"issue":"32","key":"10.1016\/j.phrs.2025.107659_bib263","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.1502159112","article-title":"The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib264","doi-asserted-by":"crossref","first-page":"20979","DOI":"10.3390\/molecules201219739","article-title":"DNA aptamers in the diagnosis and treatment of human diseases","volume":"20","author":"Zhu","year":"2015","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib265","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.phrs.2025.107659_bib266","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI11325","article-title":"Developing aptamers into therapeutics","volume":"106","author":"White","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"23","key":"10.1016\/j.phrs.2025.107659_bib267","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2025.107659_bib268","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2013.300","article-title":"Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFR\u03b2 aptamer","volume":"22","author":"Camorani","year":"2014","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib269","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/mt.2012.163","article-title":"Targeting Axl with an high-affinity inhibitory aptamer","volume":"20","author":"Cerchia","year":"2012","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib270","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1021\/ja056943j","article-title":"Non-SELEX selection of aptamers","volume":"128","author":"Berezovski","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"5152","key":"10.1016\/j.phrs.2025.107659_bib271","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1126\/science.7510417","article-title":"High-resolution molecular discrimination by RNA","volume":"263","author":"Jenison","year":"1994","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.phrs.2025.107659_bib272","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv534","article-title":"Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment","volume":"43","author":"Levay","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107659_bib273","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1039\/b906788d","article-title":"RNA aptamer-based sensitive detection of SARS coronavirus nucleocapsid protein","volume":"134","author":"Ahn","year":"2009","journal-title":"Analyst"},{"issue":"2","key":"10.1016\/j.phrs.2025.107659_bib274","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ab.2005.04.013","article-title":"Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance","volume":"342","author":"Misono","year":"2005","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/j.phrs.2025.107659_bib275","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jb\/mvj095","article-title":"An efficient RNA aptamer against human influenza B virus hemagglutinin","volume":"139","author":"Gopinath","year":"2006","journal-title":"J. Biochem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:26:38Z","timestamp":1745583998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":275,"alternative-id":["S1043661825000842"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107659","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107659"}}